The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis
Open accessAbstract
Cancer remains the most devastating disease and the major cause of mortality worldwide. Although early diagnosis and treatment are the key approach in fighting against cancer, the available conventional diagnostic and therapeutic methods are not efficient. Besides, ineffective cancer cell selectivity and toxicity of traditional chemotherapy remain the most significant challenge. These limitations entail the need for the development of both safe and effective cancer diagnosis and treatment options. Due to its robust application, nanotechnology could be a promising method for in-vivo imaging and detection of cancer cells and cancer biomarkers. Nanotechnology could provide a quick, safe, cost-effective, and efficient method for cancer management. It also provides simultaneous diagnosis and treatment of cancer using nano-theragnostic particles that facilitate early detection and selective destruction of cancer cells. Updated and recent discussions are important for selecting the best cancer diagnosis, treatment, and management options, and new insights on designing effective protocols are utmost important. This review discusses the application of nanotechnology in cancer diagnosis, therapeutics, and theragnosis and provides future perspectives in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Chen, H., Kim, S., Li, L., Wang, S., Park, K., & Cheng, J.-X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707046105 · Cited by 394
Physical‐, chemical‐, and biological‐responsive nanomedicine for cancer therapy
Liao, J., Jia, Y., Wu, Y., Shi, K., Yang, D., Li, P., & Qian, Z. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1581 · Cited by 67
Cited by
Emerging Applications of Nanotechnology in Healthcare and Medicine
Malik, S., Muhammad, K., & Waheed, Y. (2023) · Molecules · doi:10.3390/molecules28186624 · Cited by 610
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Samad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100268 · Cited by 35
Mu, X., Mu, C., Wang, M., Meng, C., Liu, H., & Lu, H. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s552644 · Cited by 16
Metadata
- Authors
- Dessale, M., Mengistu, G., & Mengist, H. M.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2022-08
- Volume
- Volume 17
- Pages
- 3735-3749
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W4293105968
- Cited by
- 191
- References
- 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.